953742-67-1Relevant articles and documents
FUSED 1,2 THIAZOLES AND 1,2 THIAZINES WHICH ACT AS NL3P3 MODULATORS
-
Page/Page column 80; 82, (2021/01/22)
The present invention relates to novel compounds (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of the activation of a component of the inflammasome pathway. In particular, the component of the inflammasome pathway is NLRP3 inflammasome. More particularly, the compounds of the present invention have the capability to inhibit the NLRP3 inflammasome. Further, the compounds of the present invention modulate, in particular, decrease IL-1 beta and/or IL-18 levels.
Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: Dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory ac
Chowdhury, Morshed A.,Abdellatif, Khaled R.A.,Dong, Ying,Das, Dipankar,Yu, Gang,Velazquez, Carlos A.,Suresh, Mavanur R.,Knaus, Edward E.
experimental part, p. 6855 - 6861 (2010/05/19)
A novel class of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore attached to its C-4 or C-5 position was designed for evaluation as anti-inflammatory (AI) agents. Repl